Journal Watch · Arthritis & Rheumatology · 2026

18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis.

Imaging-based outcome measures should remain exploratory in future therapeutic trials.

Quinn KA, Tan S, Verdijk P et al.Arthritis & Rheumatology3 min readPharma relevance 65/100

DOI: 10.1002/art.70166PMID: 41940456Study type: randomised / controlled clinical trial

TL;DR

Imaging-based outcome measures should remain exploratory in future therapeutic trials.

Key findings

  • There were no differences in prior glucocorticoid dose (median 780 mg) or duration (median 23 days) between patients with baseline active versus inactive FDG-PET scans.
  • FDG-PET scans were active in 17 of 21 (81%) patients during clinical flare and in 14 of 20 (70%) patients at week 52.
  • Subsets of patients had persistently active (n = 21) or inactive (n = 9) PET scans at all time points, independent of clinical assessment.<h4>Conclusion</h4>Vascular FDG-PET activity may be discordant with clinical assessment, particularly in subsets of patients with GCA.
  • Imaging-based outcome measures should remain exploratory in future therapeutic trials.

Numbers at a glance (from the abstract)

n = 21n = 955%89%48%81%70%P = 0.03P < 0.01

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

FDG-PET findings were compared to clinical assessment, acute phase reactants, and glucocorticoid use at each visit.<h4>Results</h4>Baseline FDG-PET scans were interpreted as active vasculitis in 28 (55%) of 51 patients. FDG-PET activity at enrollment was not associated with clinical symptoms, acute phase reactants, or risk of flare. Younger age (70 vs 76 years; P = 0.03) and female sex (89% vs 48%, P < 0.01) were significantly associated with increased FDG-PET activity.

Full abstract (original)

Background: <h4>Objective</h4>To compare fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging to clinical- and laboratory-based assessments of disease activity in a randomized controlled trial (RCT) in giant cell arteritis (GCA).<h4>Methods</h4>Patients with new-onset or relapsing GCA were randomized to guselkumab or placebo plus tapered glucocorticoids in an international, multicenter RCT. FDG-PET was performed at the baseline visit before randomization and repeated at disease flare or the week-52 visit (clinical remission off glucocorticoids). FDG-PET scans were interpreted as active or inactive by two readers, and the PET Vascular Activity Score was calculated to quantify arterial FDG uptake.

What they did: FDG-PET findings were compared to clinical assessment, acute phase reactants, and glucocorticoid use at each visit.<h4>Results</h4>Baseline FDG-PET scans were interpreted as active vasculitis in 28 (55%) of 51 patients. FDG-PET activity at enrollment was not associated with clinical symptoms, acute phase reactants, or risk of flare. Younger age (70 vs 76 years; P = 0.03) and female sex (89% vs 48%, P < 0.01) were significantly associated with increased FDG-PET activity.

Results & conclusions: There were no differences in prior glucocorticoid dose (median 780 mg) or duration (median 23 days) between patients with baseline active versus inactive FDG-PET scans. FDG-PET scans were active in 17 of 21 (81%) patients during clinical flare and in 14 of 20 (70%) patients at week 52. Subsets of patients had persistently active (n = 21) or inactive (n = 9) PET scans at all time points, independent of clinical assessment.<h4>Conclusion</h4>Vascular FDG-PET activity may be discordant with clinical assessment, particularly in subsets of patients with GCA. Imaging-based outcome measures should remain exploratory in future therapeutic trials.

Abstract © the authors / Arthritis & Rheumatology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/art.70166 · PubMed 41940456.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Arthritis & Rheumatology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Arthritis & Rheumatology study find?

Imaging-based outcome measures should remain exploratory in future therapeutic trials.

What type of study is this?

It is a randomised / controlled clinical trial, published in Arthritis & Rheumatology in 2026. FDG-PET findings were compared to clinical assessment, acute phase reactants, and glucocorticoid use at each visit.<h4>Results</h4>Baseline FDG-PET scans were interpreted as active vasculitis in 28 (55%) of 51 patients.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/art.70166. PubMed ID: 41940456. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Quinn KA, Tan S, Verdijk P et al.. 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis.. Arthritis & Rheumatology (2026). DOI: 10.1002/art.70166.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/18f-fluorodeoxyglucose-positron-emission-tomography-imaging-assessment-w-t70166/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides